1. 266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC). (10th December 2020) Authors: Wildsmith, Sophie; Walker, Jill; L'Hernault, Anne; Li, Weimin; Bye, Hannah; He, Philip; Xiao, Feng; Zhang, Qu; Stewart, Ross; Reyes, Melissa de los; Raja, Rajiv; Levin, Wendy; Gupta, Ashok; Powles, Thomas; Bellmunt, Joaquim; Galsky, Matthew; Drakaki, Alexandra; Heijden, Michiel van der Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia Masvidal; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine A.; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy A.;... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk. (9th November 2020) Authors: Choueiri, Toni; Albiges, Laurence; Powles, Thomas; Mohamed, Nehal; Wang, Fong; Motzer, Robert Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. (6th June 2019) Authors: Michaelson, M. Dror; Gupta, Shilpa; Agarwal, Neeraj; Szmulewitz, Russell; Powles, Thomas; Pili, Roberto; Bruce, Justine Yang; Vaishampayan, Ulka; Larkin, James; Rosbrook, Brad; Wang, Erjian; Murphy, Danielle; Wang, Panpan; Lechuga, Maria Josè; Valota, Olga; Shepard, Dale R. Journal: Oncologist Issue: Volume 24:Number 9(2019) Page Start: 1151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. (March 2017) Authors: Bellmunt, Joaquin; Powles, Thomas; Vogelzang, Nicholas J. Journal: Cancer treatment reviews Issue: Volume 54(2017) Page Start: 58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Issue 5 (May 2022) Authors: Hussain, Syed A; Lester, Jason F; Jackson, Richard; Gornall, Matthew; Qureshi, Muneeb; Elliott, Anthony; Crabb, Simon J; Huddart, Robert A; Vasudev, Naveen; Birtle, Alison J; Worlding, Jane; James, Nicholas D; Parikh, Omi; Vilarino-Varela, Maria; Alonzi, Roberto; Linch, Mark D; Riaz, Irbaz B; Cat... Journal: Lancet oncology Issue: Volume 23:Issue 5(2022) Page Start: 650 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Issue 4 (April 2021) Authors: Bellmunt, Joaquim; Hussain, Maha; Gschwend, Jürgen E; Albers, Peter; Oudard, Stephane; Castellano, Daniel; Daneshmand, Siamak; Nishiyama, Hiroyuki; Majchrowicz, Martin; Degaonkar, Viraj; Shi, Yi; Mariathasan, Sanjeev; Grivas, Petros; Drakaki, Alexandra; O'Donnell, Peter H; Rosenberg, Jonathan E; ... Journal: Lancet oncology Issue: Volume 22:Issue 4(2021) Page Start: 525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Issue 10232 (18th April 2020) Authors: Birtle, Alison; Johnson, Mark; Chester, John; Jones, Robert; Dolling, David; Bryan, Richard T; Harris, Christopher; Winterbottom, Andrew; Blacker, Anthony; Catto, James W F; Chakraborti, Prabir; Donovan, Jenny L; Elliott, Paul Anthony; French, Ann; Jagdev, Satinder; Jenkins, Benjamin; Keeley, Fra... Journal: Lancet Issue: Volume 395:Issue 10232(2020) Page Start: 1268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗